BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24386429)

  • 1. Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.
    Girolamo F; Dallatomasina A; Rizzi M; Errede M; Wälchli T; Mucignat MT; Frei K; Roncali L; Perris R; Virgintino D
    PLoS One; 2013; 8(12):e84883. PubMed ID: 24386429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
    Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
    Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
    Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours.
    Chekenya M; Enger PØ; Thorsen F; Tysnes BB; Al-Sarraj S; Read TA; Furmanek T; Mahesparan R; Levine JM; Butt AM; Pilkington GJ; Bjerkvig R
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):367-80. PubMed ID: 12366818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
    Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
    J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.
    Sato S; Tang YJ; Wei Q; Hirata M; Weng A; Han I; Okawa A; Takeda S; Whetstone H; Nadesan P; Kirsch DG; Wunder JS; Alman BA
    Cell Rep; 2016 Jul; 16(4):917-927. PubMed ID: 27425618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
    Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
    Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
    Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
    Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.
    Wang J; Svendsen A; Kmiecik J; Immervoll H; Skaftnesmo KO; Planagumà J; Reed RK; Bjerkvig R; Miletic H; Enger PØ; Rygh CB; Chekenya M
    PLoS One; 2011; 6(7):e23062. PubMed ID: 21829586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature.
    Al-Mayhani MT; Grenfell R; Narita M; Piccirillo S; Kenney-Herbert E; Fawcett JW; Collins VP; Ichimura K; Watts C
    Neuro Oncol; 2011 Aug; 13(8):830-45. PubMed ID: 21798846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional roles of CSPG4/NG2 in chondrosarcoma.
    Jamil NS; Azfer A; Worrell H; Salter DM
    Int J Exp Pathol; 2016 Apr; 97(2):178-86. PubMed ID: 27292772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tunneling nanotubes evoke pericyte/endothelial communication during normal and tumoral angiogenesis.
    Errede M; Mangieri D; Longo G; Girolamo F; de Trizio I; Vimercati A; Serio G; Frei K; Perris R; Virgintino D
    Fluids Barriers CNS; 2018 Oct; 15(1):28. PubMed ID: 30290761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NG2 Proteoglycan in Pericyte Biology.
    Stallcup WB
    Adv Exp Med Biol; 2018; 1109():5-19. PubMed ID: 30523586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function.
    You WK; Yotsumoto F; Sakimura K; Adams RH; Stallcup WB
    Angiogenesis; 2014 Jan; 17(1):61-76. PubMed ID: 23925489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
    Cooney CA; Jousheghany F; Yao-Borengasser A; Phanavanh B; Gomes T; Kieber-Emmons AM; Siegel ER; Suva LJ; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
    Breast Cancer Res; 2011 Jun; 13(3):R58. PubMed ID: 21658254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors.
    Farnedi A; Rossi S; Bertani N; Gulli M; Silini EM; Mucignat MT; Poli T; Sesenna E; Lanfranco D; Montebugnoli L; Leonardi E; Marchetti C; Cocchi R; Ambrosini-Spaltro A; Foschini MP; Perris R
    BMC Cancer; 2015 May; 15():352. PubMed ID: 25935541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells.
    Guichet PO; Guelfi S; Teigell M; Hoppe L; Bakalara N; Bauchet L; Duffau H; Lamszus K; Rothhut B; Hugnot JP
    Stem Cells; 2015 Jan; 33(1):21-34. PubMed ID: 24898819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
    Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression.
    Stallcup WB; You WK; Kucharova K; Cejudo-Martin P; Yotsumoto F
    Microcirculation; 2016 Feb; 23(2):122-33. PubMed ID: 26465118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.